Keros Therapeutics (KROS) CLO Esther Cho Sells 4,485 Shares

What Happened
Esther Cho, Chief Legal Officer of Keros Therapeutics (KROS), disposed of 4,485 shares on August 18, 2026. The reported weighted-average sale price was $10.29, for aggregate proceeds of approximately $46,151. The sales were described as automatic "sell-to-cover" transactions to satisfy tax withholding obligations associated with the vesting of restricted stock units.

Key Details

• Transaction date: 2026-08-18. Form filed: 2026-08-20 (appears filed within the typical 2-business-day Form 4 window).
• Shares sold: 4,485; weighted-average price reported: $10.29; total reported proceeds: $46,151. Price range across multiple trades: $10.14–$10.50.
• Shares owned after transaction: not specified in the provided filing details.
• Footnotes: (F1) Sales were automatic under the issuer’s sell-to-cover policy (to cover taxes on RSU vesting). (F2) Price is a weighted average; the filer can provide per-trade breakdown on request. (F3) Notes an aggregate of 500 shares acquired under the company’s 2020 Employee Stock Purchase Plan (appears in filing context).
• Transaction code: S = Sale (not a purchase or option exercise).

Context
Sell-to-cover transactions are routine administrative sales to meet tax withholding when RSUs vest and are generally not considered a directional vote on company prospects. For retail investors, such sales reduce an insider’s share count but do not necessarily signal insider sentiment about the company’s future.